pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
← back to JOHNSON & JOHNSON
News mentioning $JNJ
164
stories
20d
GSK doubles down on Chimagen with $750M multiple myeloma wager
fiercebiotech
20d
J&J’s Contineum-partnered depression drug flunks another phase 2 test
fiercebiotech
21d
No more Nordisk as Novo goes it alone amid rebranding push
fiercebiotech
21d
Psychedelic therapies ride wave of public favor into FDA hearing
biospace
22d
J&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberg
fiercebiotech
24d
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
fiercebiotech
25d
A booming business on Wall Street would love more biotechs to quietly die
biopharma dive
26d
Tyra disappoints investors with bladder cancer data
biopharma dive
26d
Tyra claims Phase 2 win in bladder cancer, will advance drug to pivotal trial
endpoints
26d
Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock
fiercebiotech
27d
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
fiercebiotech
27d
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
fiercebiotech
Sep 4, 26
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
biopharma dive
Sep 4, 26
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
biospace
Sep 3, 26
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout
fiercebiotech
Sep 3, 26
The hidden scale-out problem behind CAR-T’s growth
biopharma dive
Sep 3, 26
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
fiercebiotech
Sep 1, 26
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
fiercebiotech
Aug 26, 26
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
biopharma dive
Aug 25, 26
STAT+: Pharmalittle: We’re reading about RFK Jr. vaccine disclosures, a Merck loss over Medicare prices, and more
stat
Aug 25, 26
Recon: FDA expands labels for J&J’s Imaavy, Jazz's Ziihera; Teva faces Turkish antitrust probe over patent moves
raps
Aug 24, 26
Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’
biospace
Aug 20, 26
Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’
fiercebiotech
Aug 20, 26
Why pediatric rare oncology outperforms in a volatile biotech market
biospace
Aug 18, 26
Johnson & Johnson MedTech nabs Monarch Quest 3 update for lung cancer detection
fiercebiotech
Aug 17, 26
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
fiercebiotech
Aug 17, 26
J&J hands lymphoma bispecific CAR T back to AbelZeta
biospace
Aug 17, 26
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
Aug 14, 26
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
biopharma dive
Aug 14, 26
BMS welcomes new multiple myeloma drug as generics batter current portfolio
biospace
← prev
page 2 of 6
next →
